Sorrento Therapeutics Inc. (NASDAQ: SRNE), in partnership with The Scripps Research Institute of La Jolla, have announced the publication of an article titled, “Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model,” by the American Chemical Society describing screening of a salicylanilide library in SARS-CoV-2 in cellular activity assay.
Salicyn 30 effective in animal models
Based on this screening attempt, the most effective derivative (Salicyn-30) was subsequently evaluated in a prophylactic animal model of SARS-CoV-2 infection. Salicyn-30 can potentially lower viral loads, alter critical cytokines, and alleviate severe weight loss in COVID-19 infections, according to this study. Furthermore, Salicyn-30 and other lead compounds may effectively against newly emerged SARS-CoV-2 strains based on their mode of action.
Salicylanilides in general and Salicyn-30 are prospective therapies for COVID-related diseases because of their anti-SARS-CoV-2 efficacy, cytokine inhibition effect, variant indifference, and a prior proven excellent pharmacokinetic properties.
Sorrent to enter a license agreement with Dyadic International.
The company and Dyadic International Inc. (NASDAQ: DYAI) have entered a binding term sheet to sign a Licensing Agreement. The agreement is for developing therapeutics, vaccines, and diagnostics for COVID-19, including Dyadic’s primary candidate DYAI-100, created through Dyadic’s patented and proprietary C1-Cell protein platform. Notably, the final license agreement terms will be set forth once the parties enter a definitive agreement.
Sorrento CEO Dr. Henry Ji said, “We look forward to continuing our collaboration with Dyadic, which began last year, initially with a goal of developing and commercializing a protein-based COVID-19 vaccine that can be rapidly manufactured in large quantities in our existing cGMP facilities, and stored and transported at room temperature, in order to increase access and affordability to underserved populations globally.”
Dyadic CEO Mark Emalfarb said, “We are delighted to have executed a binding term-sheet with Sorrento Therapeutics to license the C1 technology for the development and commercialization of coronavirus vaccines, therapeutics, and diagnostics, including COVID-19.”
